ABSTRACT
INTRODUCTION
Growing clinical evidence indicates that immunotherapy with NK cells is useful in the treatment of myeloid leukemia. However, in the majority of patients, the efficacy of this therapy is limited since the clinical responses are not always complete, or the disease recurs. [1] [2] [3] [4] [5] [6] [7] These clinical findings have prompted investigators to characterize the interactions of NK cells with AML cells, since the resulting information may contribute to the rationale design of strategies to optimize the efficacy of NK cell-based immunotherapy of AML. Convincing experimental and clinical evidence indicates that AML cells damage NK cells; this damage reduces the ability of NK cells to control AML cell growth and provides AML cells with the capacity to escape from NK cell immunity. The damages induced by AML cells to NK cells both in vitro and in vivo are referred to as NKCAs; they include apoptosis [8] , defective expression and function of natural cytotoxic receptors (NCRs), [9, 10] and CD16 downregulation. Scant information is available about the mechanism(s) underlying the induction of NKCAs by AML cells; although, this information may contribute to the rationale design of strategies to inhibit or counteract their induction. Therefore, in this study guided by the notion that MMP chemical inhibitors reverse CD16 down-regulation, [11] induced by AML cells, we have investigated whether MMP endogenous inhibitors are involved in the inhibition of AML cell-induced CD16 down-regulation. Furthermore, because of the association of CD16 cross-linking by mAb with the induction of NK cell apoptosis, [12] we have investigated the role of CD16 in the induction of AML-cell induced NK cell apoptosis and depletion. Lastly, taking advantage of the information generated by these experiments, we have developed a strategy to counteract the induction of NKCAs by leukemia cells.
RESULTS

NKCA induction by AML cells
Incubation of peripheral blood mononuclear cells (PBMCs) with the human AML cell line, ML-2, for 5 hours at 37°C induced: 1) CD16 down-regulation on NK cells; 2) apoptosis of NK cells as indicated by an increased frequency of Annexin-V+ NK cells as compared to the PBMCs incubated without the leukemic cell line and 3) depletion of NK cells as shown by a reduction in their number as compared to that in PBMCs incubated without the leukemia cell line. Similar results were obtained when the AML cell lines THP-1 and U937 were used; although, with some differences in the extent of changes. THP-1 cells were significantly less potent inducers of NKCAs than ML-2 and U937 cell lines ( Figure 1A) . The latter two cell lines did not differ from each other. The extent of the NKCAs induced by leukemia cells was markedly increased when NK cells incubated with leukemia cells were activated by cross-linking of CD16 mediated by its interaction with the Fc fragment of the CD157-specific mAb SY11B5. CD157 is expressed on leukemia cells but is not detectable on NK cells. These findings raise the possibility that CD16 plays a role in the induction of NKCAs by leukemic cells.
CD16 involvement in the induction of NKCAs by AML cells
To investigate a cause-effect relationship between CD16 down-regulation and induction of NKCAs by leukemia cells, CD16 was cross-linked by incubating IL-2 stimulated short term NK (STNK) cells for 5 hours at 37°C with ML-2 cells coated with the CD157-specific mAb SY11B5. Although with some differences in the degree of changes, mAb SY11B5 enhanced ML-2 cellinduced CD16 down-regulation (Figure 1 to lyse the leukemia cell lines THP-1 and U937 and their susceptibility to induction of NKCAs by these leukemia cell lines (data not shown).
To determine the extent of damage induced by ML-2 cells in STNK and LTNK cells both types of cells were subjected to 2-consecutive rounds incubation, the extent of damage induced in STNK cells by ML-2 cells was significantly lower than that induced following the first incubation with ML-2 cells (Figure 3 , panels B, and C). The reduced susceptibility of ML-2 cell-induced NKCAs of STNK cells was associated with a decreased anti-leukemia activity ( Figure 3D , upper and lower left panels). In contrast, following both the first and second incubation, with ML-2 cells, LTNK cells were resistant to ML-2 cells, and were effective in inducing damage of ML-2 cells ( Figure 3D , upper and lower right panels) suggesting that ML-2 cells reduce the frequency of STNK effector cells following their first incubation. Also, following their first incubation with IL-2 cells, viable STNK and LTNK cells, sorted from the NK and ML-2 cell preparation, induced a similar extent of ML-2 celldamage ( Figure 3 , panel E). These results suggest that STNK cells are composed of at least two subpopulations: one susceptible and the other one resistant to ML-2 cell induced NKCAs.
Inhibition by LTNK cells of ML-2 cell growth in CB17 scid mice
To compare the ability of LTNK and STNK cells to inhibit the subcutaneous growth of leukemia cells, ML-2 cells were mixed with LTNK cells or STNK cells and injected subcutaneously into CB17-scid mice. ML-2 cells injected into mice without NK cells were used as a reference control. LTNK cells significantly inhibited leukemia cell growth (P = 0.001) while STNK cells did not ( Figure 4A ). In addition, LTNK cells significantly prolonged disease free survival (DFS) (P = 0.03) and overall survival (OS) (P = 0.01) of leukemia bearing mice as compared to STNK cells ( Figure 4 , 4B, and 4C).These data suggest that LTNK cell treatment is associated with a favorable clinical course of the disease. 
Resistance to AML cell-induced NKCAs in the long-term culture setting is IL-2 independent and is in part mediated by MMPs inhibited by TIMP3
To investigate whether RNA transcription is involved in the generation of NK cell resistance to NKCAs, we tested the effect of actinomycin D on LTNK cell culture. We utilized 10 ng/ml of actinomycin D since this concentration did not affect the expression of CD16 and the percentage of NK cells present in PBMC preparations. Table 1 shows that following a 3-day culture with ML-2 cells, STNK cells underwent NKCAs and following a 10-day culture, LTNK cells became NKCA resistant. In contrast, ML-2 cells induced a significant down-regulation of CD16 expression (P = 0.004) and a trend toward significant reduction in the NK cell number (P = 0.09) in the PBMC preparations cultured in the presence of actinomycin D. These results suggest that NK cell RNA transcription is involved in the generation of AML cell-induced NKCA.
MMP activation during NK cell/leukemia cell conjugation has been recently shown to cause CD16 down-regulation in resting NK cells. Consistent with this result, chemical inhibitors of MMPs have been shown to inhibit CD16 down-regulation induced by AML cells. [11] This finding provided us with the rationale to test whether TIMP3, a potent endogenous MMP inhibitor is involved in the inhibition of NKCA induction by AML cells. To investigate this possibility, we examined the IL-2 stimulated NK cells. As shown in Figure 5 , (panel A and B), following a 10-day culture, IL-2 stimulated and resting LTNK cells were not significantly susceptible to ML-2 cell-induced NKCAs. In addition,TAPI-0 inhibited the down-regulation of CD16 on STNK cells, ( Figure 5 , panel C) and this effect was also detected when PBMCs cultured without IL-2 were used as targets ( Figure 5, panel D) . Notably, TAPI-0, at the concentration utilized did not alter the basal expression of CD16 and the percentage of NK cells. It reduced leukemia cell-induced CD16 down-regulation ( Figure 5 , panel E) and NK cell depletion ( Figure 5 , panel G) but did not affect leukemia cell-induced NK cell apoptosis ( Figure 5, panel F) . These results suggest that TIMP-3 inhibits ML-2 cell-induced CD16-downregulation and NK cell depletion but does not inhibit NK cell apoptosis.
Role of TIMP3 in LTNK cell resistance to AML cell-induced NKCAs
The ability of TAPI-0, to inhibit the induction of CD16-down-regulation and cell depletion by AML cells raised the possibility that TIMP3 may play a role in the resistance of LTNK cells to AML cell-induced NKCAs.
To prove this possibility, we measured the expression level of TIMP3 gene and protein in LTNK cells. LTNK cells displayed levels of TIMP3 gene expression ( Figure  5 , upper panel H) and protein shedding ( Figure 5 , lower panel H), in their culture supernatant, significantly higher than those found in STNK cells. Thus, in LTNK cells cultured at 37°C, the level of TIMP3 gene expression in NK cells was about 50 times higher than that in NK cells following a 3-day culture at 37°C. Similarly, following a 3 and a 10-day culture at 37°C, NK cells produced 2192±69 and 6963±59 pg/ml of soluble TIMP3, respectively. These 
DISCUSSION
The results, we have described, indicate that AML cells induce abnormalities in a fraction of both CD16+ and CD16-NK cell-subsets. They include CD16 downregulation, NK cell apoptosis, and NK cell depletion. NKCAs are reversed by long-term culture of NK cells at 37°C; this is associated with an increased ability of LTNK cells to inhibit subcutaneous ML-2 cell growth, in CB17 scid mice, leading to a DFS and OS prolongation. The resistance to NKCAs by LTNK cell culture which involves RNA transcription is associated with TIMP3 over-expression in vitro.
Our results show that STNK cells are not homogenously damaged by AML cells, but they harbour NK cell that are not damaged by AML cells. The identification of these cells is not readily apparent; although, their phenotypic and functional characterization may contribute to improving the therapeutic efficacy of immunotherapy of AML cells with NK cells.
In agreement with the results reported by Jewett et al. and by Grzywacz et al. [8, 11] we have found that leukemia cells cause CD16 down-regulation on STNK cells. This defect is likely to reflect MMP activation induced by NK cell-AML cell conjugation. As a result, CD16 antigen is trimmed and shed from NK cell surface. [11] The key role of MMPs in the generation of this abnormality is also supported by the ability of MMP drug inhibitors to reverse the CD16 down-regulation in NK cells induced by leukemia cells and phorbol ester activation. [11, 17, 18] We have shown for the first time that biological MMP inhibitors such as TIMPs can inhibit CD16 down-regulation. We have focused our attention on TIMP3 because of its unique ability to induce apoptosis in normal and tumor cells in vitro. [19, 20] CD16 antigen down-regulation is always associated with NK cell apoptosis and depletion. This association has been taken as evidence to suggest that CD16 antigen triggering plays a role in AML cell-induced NKCAs. In support of this possibility, a few studies have shown that cross-linking of CD16 antigen by the corresponding mAbs induces NK cell apoptosis [12] and anergy in Fas+ NK cells. These cells, in the presence of endogenous TNF-α, undergo apoptosis that is inhibited, in vitro, by anti-TNF-α mAb; only a minor population of NK cells remains cytotoxic and proliferates in the presence of IL-2. These findings support a role for TNF-α in the induction of NK cell apoptosis. [21] To reinforce the role of CD16 in AML-induced NKCAs, we have shown that cross-linking of CD16 on NK cells by the Fc fragment of SY11B5, a mAb with specificity for CD157 antigen expressed on leukemia cells but not on NK cells, induces CD16 down-regulation and enhances NK cell apoptosis. However, neither FAS nor TNF-α death pathways seem to be involved in the induction of NK cell apoptosis and depletion since NKCAs are not affected by caspase blockade. [14] In addition, the CD56+CD16-NK cell subset undergoes AML cell-induced apoptosis to the same extent as the CD56+CD16+ NK cell subset. Furthermore, TAPI-0 reduced CD16 down-regulation and NK cell depletion but did not inhibit NK cell apoptosis suggesting that TIMP3 may not play a role in AML cell-induced NK cell apoptosis. Because of the potential role of CD16 antigen in the generation of AML cell-induced NKCAs, we investigated whether the length of the in vitro incubation of NK cells with IL-2 causes changes in CD16 cell surface expression, STNK cells express a significantly higher CD16 expression level than LTNK cells. The mechanism underlying this difference is not readily apparent. One might speculate that changes over time of CD16 expression on NK cells are independent of MPP inhibition by TIMP3. [22, 23] TAPI-0 has inhibitory activity on a few MMPs including ADAM9, ADAM17, and MMP-1, 3, 9, and 13. 
MATERIALS AND METHODS
Antibodies and reagents
Fluorescein isothiocyanate (FITC)-conjugated mouse anti-human-CD16, phycoerythrin-(PE)-conjugated anti-CD16, phycoerythrin-cyanine-dye5 (PE-Cy5)-conjugated anti-CD3, allophycocyanin (APC)-conjugated anti-CD56, isotype-matched control monoclonal antibodies (mAbs) and FITC-annexin-V and propidium iodide (PI) were purchased from BD Bioscience (San Jose, CA). Anti-human CD157 (SY11B5) mAb was purchased from eBioscience (San Diego, CA). RPMI 1640 medium was purchased from Lonza (Milan, Italy). Recombinant IL-2 was obtained from Chiron Corporation (Emeryville, CA).
Cell lines
The human myeloid leukemia cell lines ML-2, THP-1 and U937 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), glutamine (10 mg/ml), penicillin (10U/ml) and streptomycin (10 mg/ml). Cells are part of our cell line laboratory collection. The identity of the ML-2 and U937 cell lines is monitored by a phenotypic analysis of cell surface markers. The latter is identified as CD45+HLA-A2-chondroytin sulphate proteoglycan (CSPG) 4+ while the former is identified as CD45+HLA-A2+CSPG4+. The identity of the THP-1 cells is monitored by the analysis of cell surface expression of CD45 and Fc receptor and by HLA class II allele genotyping including DRW1 and DRW2.
Isolation of peripheral blood mononuclear cells (PBMCs)
PBMCs isolated by Ficoll-Hypaque density gradient centrifugation from buffy coats obtained from the University of Tor Vergata Blood Bank donors. Lowdensity peripheral blood lymphocytes (LD-PBLs) were isolated as previously described. [13] PBMCs and LDPBLs were activated with IL-2 (200 U/mL) for 3-16 days at 37°C in RPMI 1640 medium supplemented with 10% FBS; this medium is referred to as a complete medium (CM). CD56 + cells and NK cells were isolated utilizing www.impactjournals.com/oncotarget anti-CD56 magnetic beads and the NK cell isolation kit, respectively (Miltenyi Biotec, Auburn, CA).
Flow cytometry analysis
PBMCs or magnetically sorted CD56 + cells were mixed with leukemia cells at different E/T ratio. Following a 5-18-hour incubation at 37°C in a 5% CO 2 atmosphere, cells were harvested, incubated for 30 min at 4°C with PEconjugated anti-CD16 mAb, PE-Cy5-conjugated anti-CD3 mAb, APC-conjugated anti-CD56 mAb, Then, cells were incubated for 15 min at room temperature, in the dark, with FITC-annexin-V and analyzed as already described. [14] Results were analyzed utilizing the BD Cell Quests and the Tree Star Inc. flowJo software.
Cytotoxicity assay
The standard 51 Cr-release cytotoxicity assay was performed as described. [15] Maximum Cr release was measured by incubating target cells with 5% triton-X-100. Percent of specific lysis was calculated utilizing the formula: (experimental release-spontaneous release) / (maximum release-spontaneous release) × 100. The spontaneous release was less than 10%.
Mice
Ten-week-old male CB17 SCID mice were purchased from Charles River Laboratories (Lecco, Italy) and housed in laminar flow cages. Mice were fed with sterile food and water. Mouse age at the beginning of the experiments ranged between 20-22 weeks. Mice endogenous NK cell activity was inhibited by an intraperitoneal injection of 50 ml of anti-asialo GM1 antiserum (Wako, Chemicals, Richmond, VA,) on day -3, 0, +14 and +21 utilizing as a reference time that of a subcutaneous injection of ML-2 cells or ML-2 plus NK cells.
In vivo anti-leukemia activity of short term and long term NK cells
PBMCs were cultured in CM at 37°C. Following a 3-day and a 10-day culture, PBMCs were harvested, and NK cells were negatively sorted (95% purity). Then ML-2 cells (4 × 10 6 ) were mixed with 3-day cultured NK cells (12 × 10 6 ), or with 10-day cultured NK cells (12 × 10 6 ), hereafter referred to as short term NK (STNK) cells, and long-term NK (LTNK) cells, respectively. Cell mixtures were resuspended in PBS supplemented with matrigel (Corning, Tewksbury, MA). Following a 30-min incubation at 37°C, 4 mice were injected with an ML-2-STNK cell suspension and 4 with an ML-2-LTNK cell suspension. Eight mice were injected with an ML-2 cell suspension and used as a control. Subcutaneous ML-2 cell growth was monitored 3 times weekly with calipers. Tumor volume (TV) was calculated using the formula: TV (cm3)=4/3p r 3 , where r=(length + width)/4. When tumor volume exceeded 2 cm 3 , a mouse was sacrificed.
Gene expression analysis
Following TRIzol based isolation (Life Technologies Italia, Monza, Italy) from cells, total RNA was subjected to reverse transcription using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA). Quantitative RT-PCR of TIMP3 and β-actin was performed using the TaqMan universal PCR master mix. Primers and probes of TIMP3 were purchased, from Life Technologies (Carlsbad, CA) as a kit assay product, Hs00165949_m1 (TIMP3). Gene expression was quantified as previously described. [16] Gene expression was normalized on the b-actin housekeeping gene.
Statistical analysis
Results were analyzed using a Mann-Whitney test or a paired-T-test. DFS and OS results were evaluated by a Kaplan-Meyer analysis. Differences were considered significant when the p value was < 0.05.
